| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 938.4 | 995.3 | 805.2 |
| Other income | 43.8 | 36.0 | 43.7 |
| Total income | 982.2 | 1031.2 | 848.9 |
| Profit before exceptional items & tax | 322.4 | 373.1 | 279.0 |
| Profit before tax | 322.4 | 373.1 | 279.0 |
| Net profit | 237.2 | 277.9 | 205.0 |
| Operating margin | 32.8% | 36.2% | 32.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +15.70% |
|---|---|
| Net profit, quarter on quarter | -14.60% |
| Revenue, year on year | +16.50% |
| Operating profit, year on year | +19.90% |
| Operating profit, quarter on quarter | -20.00% |
BSE results filing, NSE: GLAXO. Figures extracted from the filing.
GlaxoSmithKline Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,815.70
- Market cap
- ₹47,700 Cr
- Revenue (annual)
- ₹3,822 Cr
- Net profit (annual)
- ₹1,036 Cr
- P/E (TTM)
- 44.7×Sector 50.4×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 4.79%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from GlaxoSmithKline Pharmaceuticals Ltd
All →GlaxoSmithKline Pharmaceuticals Annual General Meeting
GSK Pharma's postal ballot approved Ms. Natland as NED and Mr. Akshikar's MD re-appointment. Both resolutions cleared with over 99% shareholder support.
GlaxoSmithKline Pharmaceuticals Earnings Call Transcript: Key Takeaways
GSK India delivered resilient FY26 results with double-digit EBITDA and PAT growth, despite muted 2% revenue growth due to significant supply disruptions from a CMO fire and vaccine shipment delays.
- Call
- Guides 10% growth
GlaxoSmithKline Pharmaceuticals Earnings Call Transcript: Key Takeaways
GSK reported muted 2% revenue growth due to supply chain disruptions at a key CMO, but delivered record-high EBITDA margins of 35% through cost optimization and a shift toward high-margin specialty products.
- Call
- Guides 10% growth
GlaxoSmithKline Pharmaceuticals Investor Presentation: Key Takeaways
GSK India delivered strong Q1 FY27 standalone performance with revenue growing 15% and PAT up 24%, driven by portfolio transformation and core brand leadership.
GlaxoSmithKline Pharmaceuticals Earnings Call: Key Takeaways
GSK Pharma Q4 FY26 earnings call highlighting 2% revenue growth, 34% EBITDA margins, and a shift toward an innovation-led specialty portfolio.
GlaxoSmithKline Pharmaceuticals Earnings Call: Key Takeaways
GSK India delivered double-digit EBITDA and PAT growth for FY26 despite supply disruptions. Performance was bolstered by a transition toward high-margin specialty oncology and adult vaccines, compensating for a muted general medicine segment.